L&k Biomed KRX:156100KOSDAQ
엘앤케이바이오 · Korean news coverage and regulatory filings, organized.
Articles, 24h6
Articles, 7 days7
DART filings, 7 days1
Articles tracked7since Sep 11
In Q2 2026, L&k Biomed reported revenue of ₩11.7bn, up 3.7% year on year, and operating profit of ₩1.3bn. L&k Biomed (엘앤케이바이오) appeared in 7 Korean news articles and 1 DART filing over the past seven days. Coverage peaked on Sep 14 with 7 articles.
L&k Biomed quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩11.7bn | +3.7% | ₩1.3bn | ₩8.0bn |
| Q1 2026 | ₩9.5bn | +6.8% | ₩106m | ₩7.9bn |
| Q4 2025 derived | ₩8.6bn | -14.1% | −₩1.2bn | −₩16.4bn |
| Q3 2025 | ₩10.1bn | +3.6% | ₩338m | ₩2.6bn |
| Q2 2025 | ₩11.3bn | +57.4% | ₩1.7bn | −₩2.3bn |
| Q1 2025 | ₩8.9bn | -2.6% | −₩145m | −₩734m |
| Q4 2024 derived | ₩10.0bn | +40.9% | ₩569m | ₩5.8bn |
| Q3 2024 | ₩9.7bn | +38.1% | ₩1.3bn | −₩827m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
L&k Biomed top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
- 6
